CeGaT GmbH expands its business division for sequencing services: Through “Research and Pharma Solutions”, the globally operating company offers individual approaches for projects from science and the pharmaceutical industry.
The Tübingen-based company, which was founded primarily as a genetic diagnostics provider, is constantly expanding its expertise and portfolio in the field of custom sequencing. It meanwhile offers services that go beyond sequencing services, such as immunomoritoring, liquid biopsy, and tumor mutation burden analyses. CeGaT is continuously investing in the newest technologies. With three company-owned NovaSeq 6000, large quantities of sample material can be analyzed within a very short time. By combining state-of-the-art equipment with human know-how, CeGaT supports numerous scientists in their work.
The repositioning is a response to the rising demand and addresses clients from the pharmaceutical industry. As a long-term partner, CeGaT provides support for the realization of their projects such as clinical studies.
Dr. Jiri Ködding, Director Operations, sees this transformation as an important step: “Our vision is to strengthen CeGaT’s position as the partner of choice for research institutions and pharmaceutical companies all over the world. Since long we have been offering more than just sequencing. The new name better describes what we stand for: Convincing individual solutions for scientific and pharmaceutical questions“.
You can find more information on the Research and Pharma Solutions portfolio here. CeGaT strives for the highest quality in the realization of research projects. For this reason, the company adopts the strict requirements of genetic diagnostics also for projects from science and the pharmaceutical sector. To guarantee high-quality standards and fast throughput times, all steps are carried out in-house. The entire process, from project design to the final report, is supervised by a dedicated project manager providing advice and support to the client. CeGaT is accredited according to CAP, CLIA, and DIN EN ISO 15189:2014.